Stockreport

Palvella Therapeutics GAAP EPS of -$1.03 misses by $0.19 [Seeking Alpha]

Palvella Therapeutics, Inc.  (PVLA) 
PDF Cash and cash equivalents of $63.6 million as of September 30, 2025, expected to fund operations into the second half of 2027. More on Palvella Therapeutics Palvell [Read more]